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CThrombin potential and traditional coagulation assay: are
they useful in exploring recurrent pregnancy loss risk?
Ilaria Romagnuoloa, Monica Attanasioa,b, Mauro Cozzolinoc,
Enrichetta Paladinob, Giancarlo Castamanb, Maria E. Cocciac,d
and Cinzia Fatinia,dAn adequate hemostatic balance is mandatory to get
successful pregnancy. Obstetric complications, such as
recurrent pregnancy loss (RPL), might be due to an
impairment of placental perfusion possibly related to an
underlying prothrombotic status. In this study, we used the
global coagulation assay, calibrated automated
thrombography and traditional coagulation assay to search
for a possible underlying hypercoagulable status in women
with history of RPL compared with uneventful pregnancy
women. Thrombin generation, Fibrinogen, factor VIII (FVIII),
Plasminogen Activator Inhibitor-1 (PAI-1) and von
Willebrand factor levels were analyzed in 92 not pregnant
unexplained RPL and 64 uneventful pregnancy women. In
RPL women, significantly higher fibrinogen, FVIII and PAI-1
levels, and thrombin generation with respect to those
observed in uneventful pregnancy women were found. By
dividing the study population into quartiles of endogenous
thrombin potential (ETP), a lower percentage of RPL women
than uneventful pregnancy women in the second quartile
was observed, whereas a higher percentage of RPL in
comparison with uneventful pregnancy women in the third
and fourth quartile was found (PU0.009). Accordingly, the
cut-off ETP of 1222.1 nmol/l was chosen; ETP above cut-off
concentration was associated with more than two-fold
increased risk of RPL (PU0.008), also after adjustment for0957-5235 Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.
opyright © 2017 Wolters Kluwer Health, Inc. Unatraditional risk factors (PU0.009). We provided evidence of
an underlying alteration of vascular network related to
increased coagulation components, and fibrinolysis
inhibitor levels in healthy women with history RPL;
therefore, calibrated automated thrombography global
assay and testing for FVIII and PAI-1 would be advisable in
clinical practice to evaluate the hypercoagulable status in
RPL women planning future pregnancy. Blood Coagul
Fibrinolysis 26:000–000 Copyright  2017 Wolters Kluwer
Health, Inc. All rights reserved.
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Recurrent pregnancy loss (RPL) affects about 1–5% of
fertile women usually before 20 weeks of gestation, and
beyond various factors including thrombophilia, chromo-
somal and anatomical abnormalities, endocrine dysfunc-
tion, immune disorders, lifestyle factors and maternal
infections [1], the underlying causes still remain unex-
plained [2]. In particular, as concerns thrombophilia,
the association between maternal mutations and RPL
is under constant debate [3,4].
During normal pregnancy, significant changes in haemo-
static pathway occur, thus representing a physiologically
adaptive mechanism useful to prevent postpartum bleed-
ing. In particular, increased clotting factors levels and
reduced natural anticoagulant concentration, as well as
altered fibrinolytic activity mainly related to elevated
Plasminogen Activator Inhibitor-1 (PAI-1) and PAI-2
levels, are described. Moreover, data from an in vitro
study evidenced increased thrombin generation in preg-
nant with respect to no pregnant women [5], and when anexcessive thrombin generation is present, trophoblast
apoptosis may occur [6].
A normal pregnancy is dependent on adequate placental
circulation and foetal vasculature. An adequate balance
between coagulation and fibrinolysis is mandatory to
avoid an excessive fibrin accumulation in placental vessel
and intervillous space, as well as a greater propensity to
undergo partial or total occlusion of placental vessels by
thrombus formation [7]. Data from clinical studies pro-
vided evidence for an association between increased
factor VIII (FVIII) concentrations and recurrent abortion
[8], as well as hypofibrinolysis, mainly related to high
PAI-1 levels, is involved in unexplained early recurrent
miscarriage [9]. Therefore, these parameters might be
used in exploring a potential prothrombotic status in
women suffered from RPL.
A prothrombotic status may determine an exaggerated
response during pregnancy, that in turn may affect both
pregnancy outcome and future women health. To date, itDOI:10.1097/MBC.0000000000000675
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Cohas been demonstrated that negative pregnancy out-
come, such as unexplained RPL, represent an indepen-
dent risk factor for subsequent long-term cardiovascular
and cerebrovascular morbidity, in particular, subsequent
risks of myocardial infarction (MI), cerebral infarction
and renovascular hypertension [10,11]. Interestingly,
data from literature showed that, even when traditional
cardiovascular risk factors, such as hypertension, dyslipi-
daemia, smoking habit, BMI, diabetes and cardiovascular
family history, are accounted for, RPL was associated
with an increased risk of arterial thrombosis (ischemic
stroke and MI) [12]; all these findings represent the
rationale for risk stratification and suggest preventive
intervention through a later follow-up of healthy women
suffering pregnancy losses.
Coagulation assays traditionally used, such as FVIII and
PAI-1, may be inadequate to assess the overall throm-
botic potential of subjects investigated; the evaluation of
thrombin production and activity through global coagu-
lation assay, such as calibrated automated thrombography
(CAT), could better highlight the presence of a procoa-
gulable status with respect to a traditional coagulation
protein assay [13]. Moreover, a correlation between single
coagulation factors, such as fibrinogen, and the global
thrombin potential performed by CAT assay has also
been reported [14].
At the best of our knowledge, only two studies investi-
gated the coagulation pathway by CAT assay in women
with history of unexplained RPL [13,15], reportingFig. 1
Flow-chart of study population.
pyright © 2017 Wolters Kluwer Health, Inc. Unauconflicting results. In this scenario we evaluated hemo-
static profile by global and traditional coagulation assays
in healthy women with history of RPL compared with
uneventful pregnancy women, to search for a possible
relationship between an underlying procoagulant status
and RPL.
Methods
Study population
The entire study population comprised 388 consecutive
white not pregnant women referred to Gender Medicine
Clinic for the Vascular Disorders in Women, Careggi
Hospital from 2014 to 2016, to be framed for vascular
risk. In Fig. 1, the flow chart of the study population
was reported.
Ninety-two out of 388 (23.7%) women experienced unex-
plained RPLs defined as three or more consecutive
pregnancy losses with the same partner before 20 weeks
of gestation; information concerning the adverse obstet-
rical outcome derived from written gynaecologists’
clinical report.
Sixty-four women (uneventful pregnancy women) who
had never had unexplained RPL and/or other pregnancy
complications, who delivered after uneventful pregnancy
(at least one living child), referred to Gender Medicine
Clinic for evaluating thrombotic risk before taking estro-
gen-progesterone therapy or for family history of vascular
disorders, were considered as controls.thorized reproduction of this article is prohibited.
CE: Swati; BCF-17-223; Total nos of Pages: 7;
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CTo identify disease free controls, and to exclude women
who were thought to have any form of vascular disease
(venous thromboembolism or arterial disease) and famil-
ial history of cardiovascular disorders, a detailed interview
was performed.
All women were investigated for hemostasis and thrombin
generation parameters at the follicular phase, after a mini-
mum of 6 months after events. None was pregnant or using
oral contraceptive from at least 8 weeks before testing.
Exclusion criteria were: history of vascular disease (venous
thromboembolism or arterial disease), the presence of
inherited and acquired thrombophilia, antiphospholipid
syndrome, diabetes mellitus, renal failure, history of pla-
centa mediated pregnancy complications (including intra-
uterine growth restriction, preeclampsia, foetal losses after
20 weeks). Pregnancy loss explained by anatomical abnor-
malities possibly contributing to pregnancy failure, chro-
mosome abnormalities (maternal or paternal carrier of a
structural chromosomal rearrangement) and endocrine or
immunological abnormalities, or intercurrent infectious
events, were also excluded. Informed written consent
for anonymous data analysis was obtained from each
woman. The investigation conformed with the principles
outlined in the Declaration of Helsinki.
Coagulation parameters
Blood samples were collected from the antecubital vein
into 0.109 mol/l trisodium citrate tubes (Vacutainer, Bec-
ton Dickinson, New Jersey, USA) in the morning, after an
overnight fasting. Plasma samples were obtained by
centrifuging blood at 2000 g for 15 min at room tem-
perature for von Willebrand factor (vWF)-ag, fibrinogen,
FVIII and at 4 8C only for PAI-1 evaluation. Complete
blood cell count was performed by using the Sysmex
XE-2100 hematology analyzer (Sysmex, Kobe, Japan).
Fibrinogen was assessed by Clauss clotting method (Sie-
mens, Marburg, Germany). Plasma PAI-1 antigen levels
were measured with commercially available ELISA kits
(PAI-1 Actibind ELISA, Technoclone, Wien, Austria).
FVIII activity was determined by a coagulation-based
assay, with deficient plasma in the presence of Pathrom-
tin (Coagulation Factor VIII, Siemens); vWF antigen
levels were detected by a turbidimetric assay (vWFAg,
Siemens).
Calibrated automated thrombography
Blood samples for CAT analysis were centrifuged at
2000 g for 15 min at room temperature. After removal
of the cells, plasma was centrifuged for a second time at
the same setting; platelet poor plasma (PPP) was stored at
80 8C until use.
We used the method described by Hemker et al. [16] and
commercialized by Thrombinoscope BV (Maastricht, the
Netherlands). According to the manufacturer’s instruc-
tions, measurements were conducted in 80ml of PPP
triggered by 20-ml PPP-reagent (tissue factor 5 pmol/l)opyright © 2017 Wolters Kluwer Health, Inc. Unain 96-well microtitre plates. Measurements were cali-
brated against the fluorescence curve obtained in the
same plasma mixed with 20-ml thrombin calibrator
(Thrombinoscope BV). Fluorogenic substrate (20ml)
were added to sample and calibrator wells, and the
fluorescence intensity was detected in a Fluoroskan
Ascent reader (Thermo Labsystems OY, Helsinki,
Finland) with a 390/460 filter set for 60 min, and the
thrombin generation curves were calculated with
Thrombinoscope software (Thrombinoscope BV).
Thrombin generation was expressed as endogenous
thrombin potential (ETP: the area under the curve that
represents the total amount of thrombin generated), peak
height (the maximum concentration of thrombin pro-
duced), velocity index (the slope between the start of
thrombin formation and the peak), lag time (the time in
minutes from initiation of the test to the start of thrombin
formation) and time to peak (the time in minutes to
generate the highest point on the curve).
Statistical analysis
Statistical analysis was performed by using the SPSS
software (Chicago, Illinois, USA) for Windows (Version
11.5, Microsoft, Washington USA).
Age and continuous variables were expressed as median
(range), and the categorical variables were expressed as
frequencies and percentages. Continuous variables were
analysed using independent samples t test or Mann–
Whitney as appropriate, and the categorical variables with
chi-square test.
To identify a possible cut-off value of ETP concentra-
tion, we divided our study population into quartiles of
controls ETP distribution (first quartile: <1102.4; second
quartile: 1102.5–1222.0; third quartile: 1222.1–1465.1;
fourth quartile: >1465.2 nmol/l). Mann–Whitney test
was performed to compare quartile distribution of ETP
between patients and controls. To analyse the ETP cut-
off accuracy, the ROC curve analysis was performed.
A logistic regression analysis was used to evaluate the
role of ETP cut-off in modulating RPL risk. Odds ratios
and 95% confidence intervals (CIs) were presented. A
P value less than 0.05 was considered to indicate
statistical significance.
Correlation analysis was measured by using the Spear-
man’s correlation test, and post-hoc multiple comparison
analysis was performed by using Tukey test.
Sample size calculation was based on data derived from
Bennett et al. [13]; in this study, by assuming a difference
of 10% in peak height between patients and controls, no
significant difference was found. Therefore, we hypoth-
esized that difference in peak height would be lower than
10%; by using their controls peak height values
(284.8 48.7), a sample size of at least 58 women for
each group was deemed sufficient to detect a differenceuthorized reproduction of this article is prohibited.
CE: Swati; BCF-17-223; Total nos of Pages: 7;
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Table 1 Demographical and Clinical characteristics of the study
population
Women with
RPL, n¼92
Control women,
n¼64 P
Demographic and clinical parameters
Agea 38 (26–42) 37 (25–40) 0.3
n % n %
Smoking habits 16 17.4 11 17.1 0.5
BMI>25 kg/m2 26 28.3 11 17.2 0.07
Familial history of CV disease 25 27.2 6 9.3 0.005
Women with history of
pregnancy loss
92 100 0 0
Three previous pregnancy
loss
67 72.8 –
Four previous pregnancy
loss
18 19.6 –
Five previous pregnancy
loss
7 7.6 –
Gravidity 386 102
Number of pregnancy loss 308 79.8 0 0
Live birth 78 20.2 102 100 0.0001
CV, cardiovascular; RPL, recurrent pregnancy loss. Bold values indicate statistical
significance. a Values are given as median (range).
Coof 9%, with a statistical power of 80% (b) and a signifi-
cance value of 5% (a).
Results
In Table 1, demographic and clinical characteristics of
the study population were shown. No significant differ-
ence in age and smoking habit between women with
RPL and controls was observed; a higher prevalence of
both BMI more than 25 kg/m2, and familial history of
cardiovascular disease was observed in women with his-
tory of RPL in comparison with that found in controls.
Among 92 women with history of pregnancy loss, 67
(72.8%) experienced three events, 18 (19.6%) four events
and 7 (7.6%) have had five consecutive losses (Table 1).
As concerns, haemostatic parameters investigated, higher
fibrinogen, FVIII and PAI-1 levels in women with RPL
compared with controls were observed; no difference in
vWF concentration between patients and controls was
found (Table 2).
By evaluating thrombin generation through the parameters
deriving from the CAT assay, we observed that ETP andTable 2 Hemostasis and thrombin generation parameters among recu
Women with RPL, n¼92
Hemostasis parameters
vW factora 106.0 (40.2–253.0)
Fibrinogen (mg/dl)a 405 (224–549)
FVIIIa 105.8 (46.5–283.0)
PAI-1 (ng/ml)a 21.6 (12.8–68.0)
Thrombin generation parameters
Lag time (min)a 2.67 (1.67–4.33)
ETP (nmol/l min)a 1412 (551–2853)
Time to peak (min)a 5.83 (4.00–11.67)
Peak (nmol/l)a 244 (46–507)
Vel index (nM/min)a 76.1 (8.0–236.0)
RPL, recurrent pregnancy loss. Bold values indicate statistical significance. a Values
pyright © 2017 Wolters Kluwer Health, Inc. Unaupeak height were significantly higher in RPL as compared
with controls; moreover, a significant lower lag time in RPL
with respect to controls was found (Table 2).
By exploiting ETP median values, we observed a signifi-
cant different distribution between RPL patients and
controls (P¼ 0.001).
To identify a cut-off of ETP concentration, which could
be associated with a high RPL risk, we divided our study
population into quartiles of controls ETP distribution. In
Fig. 2, the percentage of both RPL women and controls,
according to ETP quartiles, is reported; in particular, in
the first ETP quartile, we found the same percentage of
patients and controls, and in the second quartile a lower
percentage of RPL with respect to control women was
observed (second quartile: 33.3 vs. 66.7%, respectively); a
higher percentage of RPL in comparison with control
women in third and fourth quartile was found (third
quartile: 59.0 vs. 41.0%, respectively; fourth quartile:
70.6 vs. 29.4%, respectively) (P¼ 0.009) (Fig. 2). Based
on these results and according to controls ETP distribu-
tion, ETP concentration of 1222.1 nmol/l was considered
as cut-off value.
At the ROC curve analysis, a high specificity and sensi-
bility of the cut-off value was evidenced (Area Under
Curve¼ 0.63, P¼ 0.009).
Accordingly, the potential role of ETP cut-off value in
predicting RPL risk was investigated; our results showed
that ETP concentration above cut-off value was associ-
ated with more than two-fold increased risk of RPL
[Odds Ratio (OR)¼ 2.56, CI; 1.28–5.13, P¼ 0.008], also
after adjustment confounding variables and traditional
cardiovascular risk factors (smoking habit, BMI> 25,
familial history of cardiovascular disorders) (OR¼ 2.63,
CI; 1.28–5.41, P¼ 0.009).
We also investigated the relationship between thrombin
generation and hemostatic parameters known to affect
vascular environment, such as FVIII, PAI-1 and Fibrino-
gen (Table 3); our findings showed a positive relationship
between FVIII and PAI-1 and thrombin generation; in
particular, FVIII significantly correlated with ETP, peak
and velocity index in RPL women, but not in controls,rrent pregnancy loss and controls women
Control women, n¼64 P
104.2 (46.5–188.0) 0.9
320.5 (236–415) <0.0001
90.5 (47.0–140.0) 0.04
7.0 (2.0–48.0) <0.0001
2.61 (1.64–4.32) 0.05
1222 (840–1966) 0.009
6.00 (3.98–8.50) 0.8
209 (78–413) 0.04
63.5 (17.7–1777.0) 0.1
are given as median (range).
thorized reproduction of this article is prohibited.
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Fig. 2
Percentage of recurrent pregnancy loss women and control women
among quartiles of endogenous thrombin potential distribution.
Cwhereas PAI-1 significantly correlated with ETP in both
RPL women and control group. A significant correlation
between fibrinogen and lag time in both groups was
found. After multiple comparison analysis, FVIII,
but not PAI-1, still remained significantly correlated with
both peak and velocity index in RPL women (P¼ 0.001
and <0.0001, respectively). As concerns control women,
PAI-1 still remained significantly correlated with ETP,
peak and velocity index (P< 0.0001).
Discussion
Our results evidenced that women with history of three or
more consecutive unexplained pregnancy losses exhib-
ited higher thrombin generation than women with
uneventful pregnancy. This datum allow us to hypothe-
size a relationship between an underlying procoagulant
status, related to both thrombin generation and altered
hemostatic parameters, and negative obstetric events,
such as unexplained RPL. Moreover, in this study, weTable 3 Correlation between thrombin generation and hemostasis pa
Lag time ETP
RPL women
PAI-1 0.494
P¼0.2
0.778
PU0.01
FVIII 0.122
P¼0.4
0.508
P<0.0001
Fibrinogen 0.336
PU0.008
0.096
P¼0.4
Control Women
PAI-1 0.080
P¼0.5
0.852
P<0.0001
FVIII 0.214
P¼0.3
0.141
P¼0.5
Fibrinogen 0.334
PU0.08
0.403
PU0.03
ETP, endogenous thrombin potential; RPL, recurrent pregnancy loss. Bold values ind
opyright © 2017 Wolters Kluwer Health, Inc. Unadefine an ETP cut-off value, a measure of potential
hypercoagulability, which might be used to frame RPL
women risk profile, also in the presence of traditional
risk factors.
Really, pregnancy loss is associated with altered hemo-
stasis balance traditionally attributed to an excessive
fibrin accumulation in placental vessel and intervillous
space, as well as a greater propensity to undergo partial or
total occlusion of placental vessels by thrombus formation
[7]. Moreover, data from an experimental study suggest a
further mechanism related to thrombin, which, by acting
as cell mediator, increases trophoblast apoptosis and
impairs trophoblast invasion [6]. Accordingly, the onset
of a prothrombotic status could determine an altered
trophoblast development, and at later gestational ages
utero-placental vascular insufficiency [15]. Therefore,
based on these mechanisms, we could hypothesize that
high thrombin concentration, by acting both as signalling
molecule and hemostasis component, may increase the
risk of early or late pregnancy loss.
Thrombin levels are not only related to the amount of
prothrombin, but also to the kinetic of prothrombin
conversion reaction and thrombin inactivation; moreover,
thrombin generation is modulated by several inhibitors
and cofactors [17].
CAT assay, which measures the individual overall capac-
ity to produce thrombin, is potentially more useful to
evaluate hemostasis potential compared with conven-
tional tests, such as prothrombin activation products
(prothrombin fragment F1þ 2) and Thrombin antithrom-
bin complex levels, which can identify only a hypercoaul-
able status already existing at full rate [18]. Our results
showed increased ETP and peak parameters in RPL
women, but also a longer lag time. This datum should
be related to higher fibrinogen levels, as previously
described [19]. Really, Dielis et al. have shown, in normal
population, that fibrinogen may produce not only a pro-
coagulant effect but also an anticoagulant effect by
increasing lag time. This dual pro-coagulant/anticoagu-
lant effect can be explained by the ability of fibrinogen torameters among recurrent pregnancy loss and controls women
Time to peak Peak Vel index
0.234
P¼0.5
0.07
P¼0.8
0.017
P¼0.9
0.365
PU0.005
0.561
P<0.0001
0.557
P<0.0001
0.226
P¼0.08
0.129
P¼0.3
0.136
P¼0.2
0.176
P¼0.2
0.693
P<0.0001
0.534
P<0.0001
0.203
P¼0.4
0.099
P¼0.6
0.120
P¼0.6
0.286
P¼0.1
0.131
P¼0.5
0.065
P¼0.7
icate statistical significance.
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Cobind to thrombin through binding sites, which are needed
for the thrombin-mediated FVIII activation. This fibrin-
ogen binding leads to an anticoagulant effect in the
initiation phase, as also reported by Hemker et al. [14]
who compared thrombin generation in full and defibrin-
ated plasma.
At the best of our knowledge, only two studies were
performed by using CAT assay in women with history of
RPL [13,20], reporting conflicting results. Data from
Bennett et al. [13] did not provide evidence of a procoa-
gulant status in RPL women, even if an increase in ETP
and peak height was found. Although several likenesses
in both patients enrolment and exclusion criteria were
present, some differences existed between our and data
from Bennett, in particular ethnicity and timing of preg-
nancy losses; moreover, our study was conducted in a
larger cohort of patients.
Another study, by investigating in RPL women the
relationship between thrombin generation and pregnancy
losses, evidenced enhanced thrombin generation, in par-
ticular when the assay was performed in the presence of
thrombomodulin [20]. This datum is in keeping with our
results in highlighting a procoagulant status in RPL
women; however, our findings, obtained in the absence
of thrombomodulin, and referred to a study population
free from vascular events and thrombophilia, seem to be
more notable. The addition of thrombomodulin could
unmask alterations in protein C pathway, related to
thrombotic events [21]; therefore, thrombin generation
assay in presence of thrombomodulin is fitting in study
population with history of vascular events, as is reported
in the study from de Saint Martin.
To date, the evidence of hypercoagulability in RPL
women, apart from clinical events, is supported by data
from Rai et al. [15] who used another global coagulation
assay, the thromboelastography. We did not perform
thromboelastography assay, which is sensitive to cellular
and plasmatic components and explores both clot forma-
tion and its breakdown, and this represent a limitation of
our study. On the other hand, we evaluated both coagu-
lation and fibrinolysis markers, such as fibrinogen, FVIII
and PAI-1, demonstrating higher concentrations of these
parameters in women with history of RPL, in keeping
with data from global assays. Of interest, our results
provided evidence for a significant correlation between
FVIII levels and CAT parameters in patients, but not in
controls, thus underling the role of this factor in main-
taining a thrombophilic condition in RPL women outside
of pregnancy, as previously reported [8,22].
Another limitation of our study is the lack of information
concerning follow-up of women with history of RPL, as
RPL represents an independent risk factor for subse-
quent long-term cardiovascular and cerebrovascular
events [12]. Therefore, the identification of women with
underlying hypercoagulable status, apart from the clinicalpyright © 2017 Wolters Kluwer Health, Inc. Unauevent, might pave the way to a possible therapeutic
approach in controlling their future risk.
Conclusion
In conclusion, we demonstrated, by using the global
CAT assay, an underlying alteration of vascular network
related to increased coagulation components, and
fibrinolysis inhibitor levels in women with history of
unexplained RPL and free from vascular events and
thromophilic defects. Therefore, we could suggest
that CAT global assay and routine testing for FVIII
and PAI-1 should be used in clinical practice to evaluate
the hypercoagulable status in healthy RPL women
planning future pregnancy. If these data are confirmed
in larger studies, it will be intriguing to speculate
whether the hypercoagulable profile will be of value
in the setting of antithrombotic strategies in unex-
plained RPL women.
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